GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cryofocus Medtech (Shanghai) Co Ltd (HKSE:06922) » Definitions » Additional Paid-In Capital

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Additional Paid-In Capital : HK$320.05 Mil(As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cryofocus Medtech (Shanghai) Co Additional Paid-In Capital?


Cryofocus Medtech (Shanghai) Co's quarterly additional paid-in capital declined from Dec. 2023 (HK$327.88 Mil) to Jun. 2024 (HK$322.71 Mil) but then stayed the same from Jun. 2024 (HK$322.71 Mil) to Dec. 2024 (HK$320.05 Mil).

Cryofocus Medtech (Shanghai) Co's annual additional paid-in capital declined from Dec. 2022 (HK$334.76 Mil) to Dec. 2023 (HK$327.88 Mil) and declined from Dec. 2023 (HK$327.88 Mil) to Dec. 2024 (HK$320.05 Mil).


Cryofocus Medtech (Shanghai) Co Additional Paid-In Capital Historical Data

The historical data trend for Cryofocus Medtech (Shanghai) Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryofocus Medtech (Shanghai) Co Additional Paid-In Capital Chart

Cryofocus Medtech (Shanghai) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
- 184.45 334.76 327.88 320.05

Cryofocus Medtech (Shanghai) Co Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Additional Paid-In Capital Get a 7-Day Free Trial 334.76 327.88 327.88 322.71 320.05

Cryofocus Medtech (Shanghai) Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Cryofocus Medtech (Shanghai) Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cryofocus Medtech (Shanghai) Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryofocus Medtech (Shanghai) Co Business Description

Traded in Other Exchanges
N/A
Address
Lane 3399, Kangxin Road, Building 15, Pudong New Area, Shanghai, CHN, 200120
Cryofocus Medtech (Shanghai) Co Ltd is a medical device company engaged in the research and development, manufacture, and sale of cryoablation minimally invasive interventional treatment technology and related medical products. The products offered by the company include; Bladder Cryoablation System, Pulmonary Nodule Localization Needle, and Endoscopic Clip for Anastomosis among others. Geographically, the company's revenue is generated from the sale of medical consumables and devices in the Chinese Mainland.
Executives
Zhuhai Junheng Investment L.p. (limited Partnership) 2101 Beneficial owner
Shang Hai Shi Di Sheng Wu Ke Ji You Xian Gong Si
Lv Shiwen 2103 Interests held jointly with another person
Shenzhen Gao Ling Tiancheng Iii Investment Co., Ltd. 2201 Interest of corporation controlled by you
Ning Bo Lin Feng Sheng Wu Ke Ji You Xian Gong Si
Wu Jianhui 2101 Beneficial owner
Li Hui 2202 Interest of your spouse
Shang Hai Shi Di Shi Ye Fa Zhan You Xian Gong Si
Sun Xiaolu 2201 Interest of corporation controlled by you
Fu Guo Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Hang Zhou Bi Lin Xing Chuang Xin Tou Zi He Huo Qi Ye You Xian He Huo
Shang Hai Bi Lin Xing Zi Chan Guan Li You Xian Gong Si
Hang Zhou Bi Lin Xing Chuang Xin Tou Zi Guan Li He Huo Qi Ye You Xian He Huo
Sheng Shan Zi Chan Guan Li Shang Hai You Xian Gong Si
Gan Shi Xiong

Cryofocus Medtech (Shanghai) Co Headlines

No Headlines